afhankleijkheid meting van huidskleur not applicable
Conditions
Interventions
fluorescence
skin colour
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 6 healthy persons and 6 patients with diabetes with a wide age range, all with a dark (Fitzpatrick class IV-VI) skin colour
Exclusion criteria
Exclusion criteria: skin disease ot other local skin abnormalities (such as scars or tattoos)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following measurements, and two 3 mm punch skin biopsies will be performed on the volar sitd of one of the forearms approximately 10 cm below the elbow fold: - In vivo skin autofluorescence and reflection measurements, with the conventional research version of the AGE readers ((which includes a high-quality spectrometer) - Measurement of skin colour and type using non-invasive Mexameter. - In vivo skin diffuse optical spectroscopy for the assessment of optical properties of the skin measurements will be made by a non-invasive instrument of Quaspec. - Standard biochemical assay of one of the conventional 3-mm skin biopsies for the assessment of concentrations of the following advanced glycation endproducts, pentosidine, CML and MGH-1 with use of UPLC and tandem mass spectroscopy - light microscopy of the other skin punch biopsy. In transversal coupes autofluorescence measurements will be performed with a set of different excitation wavelengths, including 370 nm, similar to that of the AGE reader. Next, in contiguous slices of this skin biopsy, imaging will be performed using AGE antibodies to assess the spatial distribution of autofluorescence and of specific advanced glycation endproducts. Candidates for the antibody AGE dose against pentosidine, CML and MGH-1. This part of the studies will be performed in corporation with the Department of Dermatology UMCG and the UMIC UMCG. | — |
Secondary
| Measure | Time frame |
|---|---|
| n.a. | — |
Countries
The Netherlands
Outcome results
None listed